The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination.
Reuters reported that the agency also recommended that the company review its quality control process.
Emergent had said the FDA had last inspected its facility at Camden in February earlier this month and was waiting for the agency's feedback.
The contract drugmaker said it was also conducting additional reviews with a third party in the meantime to ensure "delivery of medically necessary products."
Price Action: EBS shares closed at $30.50 on Friday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.